World Endometriosis Society (WCE 2023)

Dolmans, Marie-Madeleine, World Endometriosis Society (WCE 2023)
2023 · W7035106802
article OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex
⚙ AI-generated summary by qwen3.7-flash, 2026-09-26 ⓘ

The authors report key secondary efficacy endpoints from the phase 3 Edelweiss 3 trial, a randomized, double-blind, placebo-controlled study evaluating Linzagolix for managing endometriosis-associated pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-26 · read from full text ⓘ

This entry represents a conference abstract presented at the World Endometriosis Society meeting in Edinburgh rather than a full peer-reviewed research paper. The abstract reports key secondary efficacy endpoints from the Edelweiss 3 trial, which was a phase 3, randomized, double-blind, placebo-controlled study evaluating Linzagolix for endometriosis-associated pain. The document serves as a record of scientific communication regarding this specific pharmacological intervention within the context of the society's annual gathering. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

"Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial"
Full text 720 characters · extracted from oa-html · click to expand
World Endometriosis Society (WCE 2023) (2023) World Endometriosis Society (WCE 2023) — Location: Edinburgh, Scotland (4.May.2023) Site under maintenance: search & exportation results could be inconsistent. (2023) World Endometriosis Society (WCE 2023) — Location: Edinburgh, Scotland (4.May.2023) Open Access - Adobe PDF - 1.19 MB - Authors - Author - Abstract - "Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial" - Affiliations - APA - Chicago - FWB Dolmans, M.-M. (2023). World Endometriosis Society (WCE 2023). World Endometriosis Society (WCE 2023), Edinburgh, Scotland. https://hdl.handle.net/2078.5/266911

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-11T07:36:30.303065+00:00
License: CC0 · commercial use OK